Novo-Nordisk A/S (NVO) DIvidends Date & History

Key Takeaways

• Novo Nordisk offers a current dividend yield of approximately 4.1%, attractive for income-focused investors.
• The company pays dividends semi-annually, with the latest payment of $0.87 per share in April 2026.
• Payout ratio stands at around 50%, indicating strong sustainability backed by robust earnings and cash flows.
• Dividend has grown at an average annual rate of over 20% in the past five years, reflecting consistent increases.
• Financial health supports ongoing payments, with high profit margins (33%) and return on equity (60%).
• Compared to peers, NVO's yield is competitive in the pharmaceutical sector.

Dividend Overview

Novo Nordisk maintains a progressive dividend policy, returning excess capital to shareholders after funding growth and potential acquisitions. The company applies a pharmaceutical industry-standard payout ratio, supplemented by share repurchases. As of early May 2026, the trailing twelve-month (TTM) dividend yield is 4.11%, with an annual payout of $1.80 per share. Dividends are paid semi-annually, typically an interim dividend in August and a final dividend following the annual general meeting in March. Recent payments include DKK 11.70 total for 2025 (equivalent to roughly $1.75 TTM in ADR terms), underscoring its profile as a reliable dividend growth stock rather than a high-yield play.

Dividend History and Growth

Novo Nordisk has a history of consistent dividend increases without cuts, aligning with its strategy to reward long-term shareholders. Over the past five years, the dividend has grown at an average annual rate of 20.14%, with three-year growth at 27.8%. For 2025, the total dividend was DKK 11.70 per DKK 0.10 share, up from prior years, reflecting strong cash generation from its GLP-1 portfolio. While not a Dividend Aristocrat with 25+ consecutive years of increases on the U.S. listing, its track record demonstrates commitment to growth, supported by annual general meeting approvals.

Dividend Sustainability and Payout Ratio

The dividend appears highly sustainable, with a payout ratio of approximately 50.4%, well below levels that strain earnings. Earnings coverage is robust, bolstered by a 33.14% profit margin and 44.53% operating margin (TTM). Free cash flow remains positive, though levered FCF (TTM) is $376.88 million, amid investments in growth. Debt-to-equity ratio of 67.49% (most recent quarter) is manageable, with operating cash flow covering debt effectively. High return on equity (60.7%) and overall financial stability from blockbuster products like Ozempic and Wegovy position NVO to maintain and potentially grow its dividend.

Dividend Compared to Industry Peers

In the pharmaceutical industry, NVO's 4.1% yield stands out as above average for growth-oriented peers. Eli Lilly (LLY) offers a lower yield around 0.6-1%, prioritizing reinvestment in its weight-loss drugs. Merck (MRK) yields about 3%, while Pfizer (PFE) and AbbVie (ABBV) provide higher yields near 6%, reflecting more mature portfolios. NVO balances competitive yield with superior growth, appealing to investors seeking both income and appreciation in biotech/pharma.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. It efficiently identifies dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more effectively than manual screening. Explore the AI Screener to enhance your research today.

Is This Stock Attractive for Dividend Investors?

Novo Nordisk suits dividend growth investors who prioritize companies with accelerating payouts and strong fundamentals over ultra-high yields. Its 20%+ five-year growth rate and 50% payout ratio offer a blend of income reliability and upside potential, ideal for those comfortable with pharmaceutical sector volatility tied to drug pipelines. Income investors may appreciate the 4.1% yield, which exceeds many growth peers like LLY, while providing semi-annual cash flows. Long-term holders benefit from the company's capital return policy, including repurchases alongside dividends. However, conservative investors might note the current ratio of 0.8 and rising debt-to-equity, suggesting monitoring amid competitive pressures in GLP-1 markets. Overall, NVO appeals to balanced portfolios seeking sustainable income with growth exposure, though sector risks like patent cliffs warrant diversification.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations